N
Nathalie Gallay
Researcher at François Rabelais University
Publications - 35
Citations - 2216
Nathalie Gallay is an academic researcher from François Rabelais University. The author has contributed to research in topics: Bone marrow & Receptor. The author has an hindex of 16, co-authored 33 publications receiving 2002 citations. Previous affiliations of Nathalie Gallay include Institut national de la recherche agronomique & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities
Adriana López Ponte,Emeline Marais,Nathalie Gallay,Alain Langonné,Bruno Delorme,Olivier Herault,Pierre Charbord,Jorge Domenech +7 more
TL;DR: The in vitro migration capacity of human BM‐derived MSCs, preincubated or not with the inflammatory cytokines interleukin 1β (IL1β) and tumor necrosis factor α (TNFα), in response to 16 growth factors and chemokines is compared.
Journal ArticleDOI
Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells
Bruno Delorme,Jochen Ringe,Nathalie Gallay,Yves Le Vern,Dominique Kerboeuf,Christian Jorgensen,Philippe Rosset,Luc Sensebé,Pierre Layrolle,Thomas Häupl,Pierre Charbord +10 more
TL;DR: The plasma membrane protein phenotype of human culture-amplified and native bone marrow mesenchymal stem cells is studied, and the new marker CD200, because of its specificity and immunomodulatory properties, deserves further in-depth studies.
Journal ArticleDOI
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
Sophie Park,Nicolas Chapuis,Nicolas Chapuis,Valérie Bardet,Jerome Tamburini,Jerome Tamburini,Nathalie Gallay,Lise Willems,Lise Willems,Zachary A. Knight,Kevan M. Shokat,Nabih Azar,Franck Viguié,Norbert Ifrah,Francois Dreyfus,Patrick Mayeux,Patrick Mayeux,Catherine Lacombe,Didier Bouscary +18 more
TL;DR: It is demonstrated that multitargeted therapy against PI3K/Akt and mTOR with PI-103 may be of therapeutic value in AML.
Journal ArticleDOI
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
Nathalie Gallay,C Dos Santos,C Dos Santos,Lise Cuzin,Marina Bousquet,Marina Bousquet,V Simmonet Gouy,Claire Chaussade,Michel Attal,Bernard Payrastre,Bernard Payrastre,Cécile Demur,Cécile Demur,Christian Recher,Christian Recher +14 more
TL;DR: The specific Akt inhibitor, Akti-1/2, inhibited cell proliferation and clonogenic properties, and induced apoptosis in AML cells with high- risk cytogenetics, suggesting that Akt may represent a therapeutic target in high-risk AML.
Journal ArticleDOI
Competing G protein-coupled receptor kinases balance G protein and β-arrestin signaling.
Domitille Heitzler,Guillaume Durand,Nathalie Gallay,Aurélien Rizk,Seungkirl Ahn,Jihee Kim,Jonathan D. Violin,Laurence Dupuy,Christophe Gauthier,Vincent Piketty,Pascale Crépieux,Anne Poupon,Frédérique Clément,François Fages,Robert J. Lefkowitz,Eric Reiter +15 more
TL;DR: It is demonstrated that, in addition to its well‐established function in the desensitization of G‐protein activation, GRK2 exerts a strong negative effect on β‐arrestin‐dependent signaling through its competition with GRK5 and 6 for receptor phosphorylation.